In a single-centre MRS sub-study of the OBOE trial, myo-inositol fell over 2 years of ocrelizumab in both relapsing (p=0.016) and primary progressive MS (p=0.004), moving toward healthy-control levels; N-acetylaspartate stayed stable.
RCT
MacMillan et al. Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab